A Reminder                        May 8, 2013

By Leonard Zwelling

                A major effort by a new company to develop targeted therapy is set back by the FDA.

                Questions arise about the connection between the company and the President of MD Anderson.

                Filings showed that the President of MD Anderson made millions on a single day in selling the company’s stock.

                Questions arise about the independence of the President of MD Anderson and the leaders of the company with regard to drug development and stock interests.

                The question of conflicts-of-interest is raised by the press.

                May 2013?

                Nope, December 2001.

                Aveo?

                Nope, ImClone.

                Déjà vu?

                Mais non. Vuja de.